Barclays analyst Etzer Darout lowered the firm’s price target on Vir Biotechnology (VIR) to $24 from $31 and keeps an Overweight rating on the shares as part of a Q4 earnings preview for the biotechnology group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology: Strengthening Best-in-Class HDV Profile with Robust SOLSTICE Data, Strategic Partnerships, and Sufficient Cash Runway Supporting Buy Rating
- H.C. Wainwright says Vir’s SOLSTICE 96-week data reinforces best-in-class
- Vir Biotechnology updates on chronic hepatitis delta and oncology programs
- Vir Biotechnology advances hepatitis delta program and cash runway
- Vir Biotechnology price target lowered to $13 from $14 at BofA